Babaodan Overcomes Cisplatin Resistance in Cholangiocarcinoma Via Inhibiting YAP1

Overview

Journal Pharm Biol

Specialties Pharmacology
Pharmacy

Date 2024 Apr 4

PMID 38571483

Authors

Jiong Li

Xiangjun Ma

Faying Xu

Yuanliang Yan

Weiqing Chen

Affiliations

Soon will be listed here.

Abstract

Context: Cholangiocarcinoma with highly heterogeneous, aggressive, and multidrug resistance has a poor prognosis. Although babaodan (BBD) combined with cisplatin improved non-small cell lung cancer efficacy, its impact on overcoming resistance in cholangiocarcinoma remains unexplored.

Objective: This study explored the role and mechanism of BBD on cisplatin resistance in cholangiocarcinoma cells (CCAs).

Materials And Methods: Cisplatin-resistant CCAs were exposed to varying concentrations of cisplatin (25-400 μg/mL) or BBD (0.25-1.00 mg/mL) for 48 h. IC values, inhibition ratios, apoptosis levels, DNA damage, glutathione (GSH) levels, oxidized forms of GSH, total GSH content, and glutaminase relative activity were evaluated using the cell counting kit 8, flow cytometry, comet assay, and relevant assay kits.

Results: BBD-reduced the cisplatin IC in CCAs from 118.8 to 61.83 μg/mL, leading to increased inhibition rate, apoptosis, and DNA damage, and decreased expression of B-cell lymphoma-2, p-Yes-associated protein 1/Yes-associated protein 1, solute carrier family 1 member 5, activating transcription factor 4, and ERCC excision repair 1 in a dose-dependent manner with maximum reductions of 78.97%, 51.98%, 54.03%, 56.59%, and 63.22%, respectively; bcl2-associated X and gamma histone levels were increased by 0.43-115.77% and 22.15-53.39%. The impact of YAP1 knockdown on cisplatin-resistant CCAs resembled BBD. GSH, oxidized GSH species, total GSH content, and glutaminase activity in cisplatin-resistant CCAs with BBD treatment also decreased, while YAP1 overexpression countered BBD's effects.

Discussion And Conclusion: This study provides a scientific basis for BBD clinical application and provides a new direction for BBD biological mechanism research.

Citing Articles

Tailoring traditional Chinese medicine in cancer therapy.

Li S, Chen X, Shi H, Yi M, Xiong B, Li T Mol Cancer. 2025; 24(1):27.

PMID: 39838407 PMC: 11749133. DOI: 10.1186/s12943-024-02213-6.

A bird's eye view of mitochondrial unfolded protein response in cancer: mechanisms, progression and further applications.

Zhang X, Fan Y, Tan K Cell Death Dis. 2024; 15(9):667.

PMID: 39261452 PMC: 11390889. DOI: 10.1038/s41419-024-07049-y.

References

Chaouhan H, Jha R, Patel D, Chowdhuri D . Cr(VI)-induced DNA damage is lessened by the modulation of hsp70 via increased GSH de novo synthesis in Drosophila melanogaster. J Biochem Mol Toxicol. 2021; 35(8):e22819. DOI: 10.1002/jbt.22819. View

Banales J, Marin J, Lamarca A, Rodrigues P, Khan S, Roberts L . Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17(9):557-588. PMC: 7447603. DOI: 10.1038/s41575-020-0310-z. View

Liu C, Hua K, Li K, Kao H, Hong R, Ko J . Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther. 2017; 16(7):1421-1434. DOI: 10.1158/1535-7163.MCT-16-0567-T. View

Liu Z, Peng Q, Li Y, Gao Y . Resveratrol enhances cisplatin-induced apoptosis in human hepatoma cells via glutamine metabolism inhibition. BMB Rep. 2018; 51(9):474-479. PMC: 6177506. View

Zhang X, Heng Y, Kooistra S, van Weering H, Brummer M, Gerrits E . Intrinsic DNA damage repair deficiency results in progressive microglia loss and replacement. Glia. 2020; 69(3):729-745. PMC: 7821301. DOI: 10.1002/glia.23925. View

Yao W, Guo P, Mu Q, Wang Y . Exosome-Derived Circ-PVT1 Contributes to Cisplatin Resistance by Regulating Autophagy, Invasion, and Apoptosis Via miR-30a-5p/YAP1 Axis in Gastric Cancer Cells. Cancer Biother Radiopharm. 2020; 36(4):347-359. DOI: 10.1089/cbr.2020.3578. View

Huang D, Zhang X, Zhang C, Li H, Li D, Hu Y . 2,4-Dichlorophenol induces DNA damage through ROS accumulation and GSH depletion in goldfish Carassius auratus. Environ Mol Mutagen. 2018; 59(9):798-804. DOI: 10.1002/em.22209. View

Wilkins H, Marquardt K, Lash L, Linseman D . Bcl-2 is a novel interacting partner for the 2-oxoglutarate carrier and a key regulator of mitochondrial glutathione. Free Radic Biol Med. 2011; 52(2):410-9. PMC: 3253244. DOI: 10.1016/j.freeradbiomed.2011.10.495. View

Mohajan S, Jaiswal P, Vatanmakarian M, Yousefi H, Sankaralingam S, Alahari S . Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer. Cancer Lett. 2021; 507:112-123. PMC: 10370464. DOI: 10.1016/j.canlet.2021.03.006. View

10.

Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A . Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Front Oncol. 2022; 12:1021632. PMC: 9748615. DOI: 10.3389/fonc.2022.1021632. View

11.

Rodrigues P, Olaizola P, Paiva N, Olaizola I, Agirre-Lizaso A, Landa A . Pathogenesis of Cholangiocarcinoma. Annu Rev Pathol. 2020; 16:433-463. DOI: 10.1146/annurev-pathol-030220-020455. View

12.

Liu J, Chen Y, Cao Z, Guan B, Peng J, Chen Y . Babao Dan inhibits the migration and invasion of gastric cancer cells by suppressing epithelial-mesenchymal transition through the TGF-β/Smad pathway. J Int Med Res. 2020; 48(6):300060520925598. PMC: 7294507. DOI: 10.1177/0300060520925598. View

13.

Kennedy L, Sandhu J, Harper M, Cuperlovic-Culf M . Role of Glutathione in Cancer: From Mechanisms to Therapies. Biomolecules. 2020; 10(10). PMC: 7600400. DOI: 10.3390/biom10101429. View

14.

Ge X, Huang S, Ren C, Zhao L . Taurocholic Acid and Glycocholic Acid Inhibit Inflammation and Activate Farnesoid X Receptor Expression in LPS-Stimulated Zebrafish and Macrophages. Molecules. 2023; 28(5). PMC: 10003765. DOI: 10.3390/molecules28052005. View

15.

Sugiura K, Mishima T, Takano S, Yoshitomi H, Furukawa K, Takayashiki T . The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma. Am J Pathol. 2019; 189(9):1863-1877. DOI: 10.1016/j.ajpath.2019.05.014. View

16.

Chen P, Liu X, Lin X, Gao L, Zhang S, Huang X . Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism. Mol Ther Oncolytics. 2021; 20:228-239. PMC: 7873577. DOI: 10.1016/j.omto.2021.01.001. View

17.

Yang L, He K, Yao S, Zhang Y, Shen J . Sevoflurane inhibits neuroblastoma cell proliferation and invasion and induces apoptosis by miR-144-3p/YAP1 axis. Basic Clin Pharmacol Toxicol. 2021; 129(4):297-307. DOI: 10.1111/bcpt.13629. View

18.

Jia Y, Zhang W, Liu H, Peng L, Yang Z, Lou J . Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol. 2011; 69(2):377-85. DOI: 10.1007/s00280-011-1708-7. View

19.

Tusskorn O, Prawan A, Senggunprai L, Kukongviriyapan U, Kukongviriyapan V . Phenethyl isothiocyanate induces apoptosis of cholangiocarcinoma cells through interruption of glutathione and mitochondrial pathway. Naunyn Schmiedebergs Arch Pharmacol. 2013; 386(11):1009-16. DOI: 10.1007/s00210-013-0906-8. View

20.

Yoo H, Park S, Nam M, Kang J, Kim K, Yeo J . A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells. Cell Metab. 2019; 31(2):267-283.e12. DOI: 10.1016/j.cmet.2019.11.020. View